title: The molecular pruning of a phosphoramidate peptidomimetic inhibitor of prostate-specific membrane antigen.
abstract: To identify the pharmacophore of a phosphoramidate peptidomimetic inhibitor of prostate-specific membrane antigen (PSMA), a small analog library was designed and screened for inhibitory potency against PSMA. The design of the lead inhibitor was based upon N-acyl derivatives of endogenous substrate folyl-gamma-Glu and incorporates a phosphoramidate group to interact with the PSMA catalytic zinc atoms. The scope of the analog library was designed to test the importance of various functional groups to the inhibitory potency of the lead phosphoramidate. The IC(50) for the lead phosphoramidate inhibitor was 35 nM while the IC(50) values for the analog library presented a range from 0.86 nM to 4.1 microM. Computational docking, utilizing a recently solved X-ray crystal structure of the recombinant protein, along with enzyme inhibition data, was used to propose a pharmacophore model for the PSMA active site.
authors.affiliation: Department of Chemistry & Biochemistry, San Francisco State University, 1600 Holloway Avenue, San Francisco, CA 94132, USA.
authors.forename: Lisa Y
authors.initials: LY
authors.lastname: Wu
authors.forename: Marc O
authors.initials: MO
authors.lastname: Anderson
authors.forename: Yoko
authors.initials: Y
authors.lastname: Toriyabe
authors.forename: Jack
authors.initials: J
authors.lastname: Maung
authors.forename: Tammy Y
authors.initials: TY
authors.lastname: Campbell
authors.forename: Cheryl
authors.initials: C
authors.lastname: Tajon
authors.forename: Marat
authors.initials: M
authors.lastname: Kazak
authors.forename: Jamie
authors.initials: J
authors.lastname: Moser
authors.forename: Clifford E
authors.initials: CE
authors.lastname: Berkman
mesh_terms: D000577:Amides / Q000138:chemical synthesis / Q000737:chemistry / Q000494:pharmacology*; D000954:Antigens, Surface / Q000737:chemistry; D001665:Binding Sites; D003198:Computer Simulation; D018360:Crystallography, X-Ray; D015195:Drug Design; D043425:Glutamate Carboxypeptidase II / Q000037:antagonists & inhibitors* / Q000737:chemistry; D006801:Humans; D008297:Male; D008958:Models, Molecular; D015394:Molecular Structure; D009842:Oligopeptides / Q000138:chemical synthesis / Q000737:chemistry / Q000494:pharmacology*; D009942:Organometallic Compounds / Q000737:chemistry; D010756:Phosphoric Acids / Q000138:chemical synthesis / Q000737:chemistry / Q000494:pharmacology*; D011994:Recombinant Proteins / Q000037:antagonists & inhibitors / Q000737:chemistry; D054852:Small Molecule Libraries; D013237:Stereoisomerism; D013329:Structure-Activity Relationship; D015032:Zinc / Q000737:chemistry
chemical_list: D000577:Amides; D000954:Antigens, Surface; D009842:Oligopeptides; D009942:Organometallic Compounds; D010756:Phosphoric Acids; D011994:Recombinant Proteins; D054852:Small Molecule Libraries; C011067:phosphoramidic acid; C473848:FOLH1 protein, human; D043425:Glutamate Carboxypeptidase II; D015032:Zinc